Cargando…

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients

Detalles Bibliográficos
Autores principales:	Jia, Bei, Wang, Liru, Claxton, David F., Ehmann, W Christopher, Rybka, Witold B., Mineishi, Shin, Rizvi, Syed, Shike, Hiroko, Bayerl, Michael, Schell, Todd D., Hohl, Raymond J., Zheng, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862839/ https://www.ncbi.nlm.nih.gov/pubmed/29563517 http://dx.doi.org/10.1038/s41408-018-0069-4

Ejemplares similares

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
por: Wang, Liru, et al.
Publicado: (2018)

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
por: Zhao, Chenchen, et al.
Publicado: (2019)

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
por: Zhu, Liuluan, et al.
Publicado: (2017)

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
por: Kong, Y, et al.
Publicado: (2015)

A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia
por: Zheng, Hong, et al.
Publicado: (2020)

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant
por: Zhao, Chenchen, et al.
Publicado: (2022)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features
por: Teye, Emmanuel K., et al.
Publicado: (2017)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

IMPROVE-BMT: a protocol for a pilot randomised controlled trial of prehabilitation exercise for adult haematopoietic stem cell transplant recipients
por: Potiaumpai, Melanie, et al.
Publicado: (2023)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

CD26(low)PD-1(+) CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia
por: Zhou, Huarong, et al.
Publicado: (2023)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

Downregulation of CD73 associates with T cell exhaustion in AML patients
por: Kong, Yaxian, et al.
Publicado: (2019)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
por: Zuo, Zhuang, et al.
Publicado: (2012)

Transmissible ER Stress Reconfigures the AML Bone Marrow Compartment
por: Doron, Ben, et al.
Publicado: (2018)

Advances in therapeutic options for newly diagnosed, high-risk AML patients
por: Doucette, Kimberley, et al.
Publicado: (2021)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

G-CSF-Associated Bone Marrow Necrosis in AML after Induction Chemotherapy
por: Osuorji, Ikenna, et al.
Publicado: (2012)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
por: Kuszczak, Bartłomiej, et al.
Publicado: (2023)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Far from Health: The Bone Marrow Microenvironment in AML, A Leukemia Supportive Shelter
por: Sendker, Stephanie, et al.
Publicado: (2021)

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
por: Nian, Zhigang, et al.
Publicado: (2021)

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment
por: Tabe, Yoko, et al.
Publicado: (2023)

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
por: Ren, Xiying, et al.
Publicado: (2023)

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review
por: Hao, Qiukui, et al.
Publicado: (2022)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study
por: Bhayat, Fatima, et al.
Publicado: (2010)

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
por: Jagan, Sucheta, et al.
Publicado: (2012)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy
por: You, Ruolan, et al.
Publicado: (2021)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q9mddptmrg969gujo5ku53q9f6